Literature DB >> 8869935

Curable and non-curable malignancies: lessons from paediatric cancer.

A Toren1, N Amariglio, G Rechavi.   

Abstract

The tremendous progress achieved in understanding the molecular basis of cancer, was unfortunately not followed by a mutual improvement in the morbidity and mortality of adult cancer. In contrast, the success rate achieved in paediatric oncology has increased significantly during the past 30 years, and more than two-thirds of the children with cancer can now be cured. p53 has been shown to have a central role on apoptosis in various cells. As apoptosis is a final common pathway for much of our anti cancer therapy, resistance to apoptosis due to a normal activity of p53 is an important mechanism of tumor resistance and treatment failure. Contrary to the findings in most adult tumors, where about 50% of the tumors lack p53 activity, the rate of p53 mutations in childhood cancer is surprisingly low. This may be the key to the much better prognosis of children with cancer. In most adult tumors, multiple genetic events, between five and seven, are usually involved. The oncogenes involved in such tumors usually represent those located upstream of the nuclear transcription factors. In most paediatric tumors, in contrast, the initiating event is the activation of nuclear transcription factors secondary to chromosomal translocations. It can be speculated that multiple events activating various components of the signal transduction machinery are needed for tumorigenesis, and hence the evolution and progression of such tumors is slow. Moreover, if the malignant cell has to accumulate multiple mutations, the chances of crippling the apoptotic mechanism are higher. Genomic instability evidenced by microsatellite variation has been found in colon, pancreas, breast, liver and ovarian adult tumors, and not in paediatric tumors. As multiple somatic mutations are needed for the initiation and progression of the common adult malignancies, inherent genomic instability can dispose to accumulation of multiple mutations. All these molecular interactions are discussed with relevance to the difference between non-curable, mostly adult tumors, and curable, mostly paediatric tumors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8869935     DOI: 10.1007/bf02988837

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  38 in total

Review 1.  Social controls on cell survival and cell death.

Authors:  M C Raff
Journal:  Nature       Date:  1992-04-02       Impact factor: 49.962

2.  Thymocyte apoptosis induced by p53-dependent and independent pathways.

Authors:  A R Clarke; C A Purdie; D J Harrison; R G Morris; C C Bird; M L Hooper; A H Wyllie
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

Review 3.  A war not won.

Authors:  T Beardsley
Journal:  Sci Am       Date:  1994-01       Impact factor: 2.142

4.  Cell cycle. p21 inhibits cyclin shock.

Authors:  J Pines
Journal:  Nature       Date:  1994-06-16       Impact factor: 49.962

Review 5.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins.

Authors:  J E Darnell; I M Kerr; G R Stark
Journal:  Science       Date:  1994-06-03       Impact factor: 47.728

6.  The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern.

Authors:  T Takahashi; T Takahashi; H Suzuki; T Hida; Y Sekido; Y Ariyoshi; R Ueda
Journal:  Oncogene       Date:  1991-10       Impact factor: 9.867

7.  p53 status and the efficacy of cancer therapy in vivo.

Authors:  S W Lowe; S Bodis; A McClatchey; L Remington; H E Ruley; D E Fisher; D E Housman; T Jacks
Journal:  Science       Date:  1994-11-04       Impact factor: 47.728

8.  Modulation of activity of the promoter of the human MDR1 gene by Ras and p53.

Authors:  K V Chin; K Ueda; I Pastan; M M Gottesman
Journal:  Science       Date:  1992-01-24       Impact factor: 47.728

Review 9.  Cdk inhibitors: on the threshold of checkpoints and development.

Authors:  S J Elledge; J W Harper
Journal:  Curr Opin Cell Biol       Date:  1994-12       Impact factor: 8.382

10.  Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1.

Authors:  K M Dameron; O V Volpert; M A Tainsky; N Bouck
Journal:  Science       Date:  1994-09-09       Impact factor: 47.728

View more
  1 in total

Review 1.  Pro-oncogenic and anti-oncogenic pathways: opportunities and challenges of cancer therapy.

Authors:  Jiao Zhang; Yan-Hua Chen; Qun Lu
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.